• Agnieszka M Tycinska, Bozena Sobkowicz, Barbara Mroczko, Robert Sawicki, Wlodzimierz J Musial, Slawomir Dobrzycki, Ewa Waszkiewicz, Malgorzata A Knapp, and Maciej Szmitkowski.
• Department of Cardiology, Medical University, Bialystok, Poland. agnieszka.tycinska@gmail.com
• Clin. Chim. Acta. 2010 Dec 14; 411 (23-24): 2014-8.

BackgroundWe aimed to assess apelin-novel endogenous ligand for the angiotensin-like 1 receptor in patients with ST-elevation myocardial infarction (STEMI) and to compare its value with B-type natriuretic peptide (BNP).MethodsIn 78 consecutive patients with first STEMI treated with primary PCI, plasma apelin-36 (RIA) and BNP (MEIA) concentrations were measured twice: on admission and on the fifth day of hospitalization. Left ventricle ejection fraction (LVEF) was assessed on admission and composite endpoint (CEP)-after 1 year follow-up.ResultsDuring the 5-day interval median plasma BNP level significantly increased and median plasma apelin concentration significantly decreased. BNP, but not apelin, correlated with low LVEF (<50%). In ROC analysis only BNP measurements were diagnostic for low LVEF. In ANOVA test, in patients with CEP, a significant decrease in apelin (but not BNP) concentrations measured in 5-day interval was found. ROC analysis identified only second BNP measurement as significant to estimate adverse outcome 0.627 in the prediction of CEP (95% confidence interval=0.507-0.736).ConclusionFollowing STEMI there is a decrease of plasma apelin-36 concentration and an increase of plasma BNP concentration. BNP is better, than apelin diagnostic value for the detection of impaired LVEF. Both BNP and apelin have prognostic value, although both needs further evaluation.Copyright © 2010 Elsevier B.V. All rights reserved.

22 keywords...

hide…